5-Lipoxygenase expression and activity in aorta from streptozotocin-induced diabetic rats

被引:6
作者
Hardy, G
Vergnaud, S
Lunardi, J
Peoc'h, M
Bessard, G
Stanke-Labesque, F [1 ]
机构
[1] Univ Med, Lab HP2, Pharmacol Lab, F-38706 La Tronche, France
[2] Grenoble Univ Hosp, Enzymol Lab, DBPC, F-38043 Grenoble, France
[3] Grenoble Univ Hosp, Lab DNA Biochem, F-38043 Grenoble, France
[4] Grenoble Univ Hosp, Anat Pathol Lab, F-38043 Grenoble, France
关键词
5-Lipoxygenase; diabetes; leukotrienes; rat aorta; smooth muscle cells;
D O I
10.1016/j.prostaglandins.2004.10.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We previously reported an activation of the 5-lipoxygenase pathway in aorta from streptozotocin-induced diabetic rats. The aim of this study was to investigate whether this activation was associated with an increased expression of 5-lipoxygenase, an increased cysteinyl leukotriene (CysLT) production in response to arachidonic acid or calcium ionophore A23187 and/or a hypersensitivity of the aorta to CysLTs in streptozotocin-induced diabetic rats. In aorta from diabetic and control rats, reverse transcriptase-PCR and western blot analysis with a specific 5-lipoxygenase antibody provided evidence for the presence of 5-lipoxygenase in aorta. However, the expression of 5-lipoxygenase was not significantly different between diabetic and control rats. Challenge by A23187 (10 mu M) and arachidonic acid (10 mu M and 0.1 mM) with or without A23187 (10 mu mol/l) induced a significant increase of CysLT release (measured by enzyme immunoassay) that was in the same range in aorta from control and diabetic rats. In contrast, aortas from diabetic rats showed a greater sensitivity to LTC4 and LTD4 contractile effects. These data suggested that the activation of the 5-lipoxygenase pathway previously reported in streptozotocin-induced diabetic rats could be explained by an augmented sensitivity to CysLTs of the diabetic aorta. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:91 / 103
页数:13
相关论文
共 39 条
[1]   Differential leukotriene constrictor responses in human atherosclerotic coronary arteries [J].
Allen, S ;
Dashwood, M ;
Morrison, K ;
Yacoub, M .
CIRCULATION, 1998, 97 (24) :2406-2413
[2]   ENHANCED EXCRETION OF URINARY LEUKOTRIENE-E(4) IN CORONARY-ARTERY DISEASE AND AFTER CORONARY-ARTERY BYPASS-SURGERY [J].
ALLEN, SP ;
SAMPSON, AP ;
PIPER, PJ ;
CHESTER, AH ;
OHRI, SK ;
YACOUB, MH .
CORONARY ARTERY DISEASE, 1993, 4 (10) :899-904
[3]   A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease [J].
Antonipillai, I ;
Nadler, J ;
Vu, EJ ;
Bughi, S ;
Natarajan, R ;
Horton, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :1940-1945
[4]  
BALCAREK JM, 1988, J BIOL CHEM, V263, P13937
[5]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]   INCREASED URINARY LEUKOTRIENE EXCRETION IN PATIENTS WITH CARDIAC ISCHEMIA - INVIVO EVIDENCE FOR 5-LIPOXYGENASE ACTIVATION [J].
CARRY, M ;
KORLEY, V ;
WILLERSON, JT ;
WEIGELT, L ;
FORDHUTCHINSON, AW ;
TAGARI, P .
CIRCULATION, 1992, 85 (01) :230-236
[7]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[8]  
COLE OF, 1986, CELL BIOL INT REP, V10, P407, DOI 10.1016/0309-1651(86)90035-4
[9]   REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS [J].
DIXON, RAF ;
DIEHL, RE ;
OPAS, E ;
RANDS, E ;
VICKERS, PJ ;
EVANS, JF ;
GILLARD, JW ;
MILLER, DK .
NATURE, 1990, 343 (6255) :282-284
[10]   Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis [J].
Dwyer, JH ;
Allayee, H ;
Dwyer, KM ;
Fan, J ;
Wu, HY ;
Mar, R ;
Lusis, AJ ;
Mehrabian, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (01) :29-37